2026 Q3 Portfolio Activity
In 2026 Q3, Deep Track Capital, LP maintained a portfolio of 87 distinct positions. The most significant new addition was INSMED INC, now representing 2.51% of the total fund value. They heavily accumulated shares in BIOMARIN PHARMACEUTICAL INC, increasing the position by 92.7%. Conversely, Deep Track Capital, LP completely exited their position in ALNYLAM PHARMACEUTICALS INC.
Position History
hover any row below to update
Loading…
Total Positions
87
Quarter
2026 Q3
Top Holding
GH (8.2%)
Top 10 Concentration
43.3%
Turnover Rate
23.4%
Sector HHI
0.18
Items per page:
Showing 1-50 of 87
Deep Track Capital, LP Full Holdings List — 2026 Q3
| Stock | History | Sector / Type | Port % | Prev % | Rank / Prev | Conviction | Change | % Change | Influence | Shares | Mkt Value | Avg Cost | Price Held | 1st Owned | Source | Source Date | Date Reported | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
GH
GUARDANT HEALTH...
|
Healthcare | 8.15% | 7.41% |
#1
Prev: #1
|
5.8 |
—
|
-587,635 | -17.3% |
P
S
|
2,805,677 | $500,420,550 |
$32.99
+334.4%
|
2023 Q2 | 13F Filing | 2026-09-30 | 2026-11-16 | ||
|
BMRN
BIOMARIN PHARMA...
|
Healthcare | 6.23% | 2.75% |
#2
9
Prev: #11
|
7.0 |
—
|
3,066,914 | 92.7% |
P
S
|
6,374,395 | $382,463,700 | 2022 Q2 | 13F Filing | 2026-09-30 | 2026-11-16 | |||
|
IMVT
IMMUNOVANT INC
|
Healthcare | 5.04% | 5.24% |
#3
1
Prev: #2
|
3.5 |
—
|
-180,350 | -1.9% |
P
S
|
9,160,801 | $309,451,858 | 2021 Q4 | 13F Filing | 2026-09-30 | 2026-11-16 | |||
|
TARS
TARSUS PHARMACE...
|
Healthcare | 4.87% | 3.36% |
#4
3
Prev: #7
|
2.9 |
—
|
140,000 | 3.8% |
P
S
|
3,806,768 | $299,250,032 | 2025 Q1 | 13F Filing | 2026-09-30 | 2026-11-16 | |||
|
MANE
VERADERMICS INC
|
Healthcare | 3.75% | 3.58% |
#5
1
Prev: #6
|
2.5 |
—
|
-100,000 | -5.0% |
P
S
|
1,900,000 | $230,337,000 | 2026 Q1 | 13F Filing | 2026-09-30 | 2026-11-16 | |||
|
VERA
VERA THERAPEUTI...
|
Healthcare | 3.68% | 2.50% |
#6
11
Prev: #17
|
4.5 |
—
|
3,000,000 | 75.0% |
P
S
|
7,000,000 | $226,030,000 | 2025 Q4 | 13F Filing | 2026-09-30 | 2026-11-16 | |||
|
PCVX
VAXCYTE INC
|
Healthcare | 3.26% | 3.64% |
#7
3
Prev: #4
|
1.8 |
—
|
-786,931 | -18.3% |
P
S
|
3,513,069 | $199,893,626 | 2025 Q1 | 13F Filing | 2026-09-30 | 2026-11-16 | |||
|
ALKS
ALKERMES PLC
|
Healthcare | 2.97% | 3.05% |
#8
1
Prev: #9
|
3.2 |
—
|
500,000 | 12.5% |
P
S
|
4,500,000 | $182,340,000 | 2023 Q1 | 13F Filing | 2026-09-30 | 2026-11-16 | |||
|
OCUL
OCULAR THERAPEU...
|
Healthcare | 2.74% | 2.81% |
#9
1
Prev: #10
|
3.1 |
—
|
2,253,343 | 11.4% |
P
S
|
21,939,625 | $168,276,924 | 2023 Q4 | 13F Filing | 2026-09-30 | 2026-11-16 | |||
|
UTHR
UNITED THERAPEU...
|
Healthcare | 2.65% | 0.97% |
#10
24
Prev: #34
|
4.1 |
—
|
176,424 | 142.7% |
P
S
|
300,040 | $162,588,676 | 2026 Q2 | 13F Filing | 2026-09-30 | 2026-11-16 | |||
|
GPCR
STRUCTURE THERA...
|
Healthcare | 2.55% | 3.70% |
#11
8
Prev: #3
|
3.0 |
—
|
259,928 | 5.5% |
P
S
|
5,000,000 | $156,350,000 | 2023 Q1 | 13F Filing | 2026-09-30 | 2026-11-16 | |||
|
GRAL
GRAIL INC
|
Healthcare | 2.52% | 1.82% |
#12
12
Prev: #24
|
1.0 |
—
|
-730,744 | -39.8% |
P
S
|
1,104,200 | $154,720,504 | 2025 Q4 | 13F Filing | 2026-09-30 | 2026-11-16 | |||
|
INSM
INSMED INC
|
Healthcare | 2.51% | — |
#13
Prev: #—
|
4.5 |
—
|
1,350,000 | — |
NEW
|
1,350,000 | $154,089,000 | 2022 Q4 | 13F Filing | 2026-09-30 | 2026-11-16 | |||
|
CMPS
COMPASS PATHWAY...
|
Healthcare | 2.46% | 2.50% |
#14
2
Prev: #16
|
2.0 |
—
|
no change | no change |
P
S
|
12,161,496 | $151,289,010 | 2023 Q2 | 13F Filing | 2026-09-30 | 2026-11-16 | |||
|
GMAB
GENMAB A/S
|
Healthcare | 2.43% | 2.26% |
#15
4
Prev: #19
|
1.0 |
—
|
-1,467,311 | -26.0% |
P
S
|
4,182,689 | $149,217,430 | 2024 Q4 | 13F Filing | 2026-09-30 | 2026-11-16 | |||
|
AXSM
AXSOME THERAPEU...
|
Healthcare | 2.40% | 2.49% |
#16
2
Prev: #18
|
3.0 |
—
|
100,000 | 14.3% |
P
S
|
800,000 | $147,512,000 | 2023 Q2 | 13F Filing | 2026-09-30 | 2026-11-16 | |||
|
NRIX
NURIX THERAPEUT...
|
Healthcare | 2.32% | 2.73% |
#17
5
Prev: #12
|
0.9 |
—
|
-1,736,455 | -22.4% |
P
S
|
6,000,000 | $142,260,000 | 2022 Q2 | 13F Filing | 2026-09-30 | 2026-11-16 | |||
|
LBRX
LB PHARMACEUTIC...
|
Healthcare | 2.10% | 1.58% |
#18
10
Prev: #28
|
1.8 |
—
|
no change | no change |
P
S
|
3,352,804 | $128,680,617 | 2025 Q3 | 13F Filing | 2026-09-30 | 2026-11-16 | |||
|
TNGX
TANGO THERAPEUT...
|
Healthcare | 1.83% | 1.91% |
#19
3
Prev: #22
|
2.7 |
—
|
300,000 | 7.1% |
P
S
|
4,500,000 | $112,275,000 | 2025 Q3 | 13F Filing | 2026-09-30 | 2026-11-16 | |||
|
MAZE
MAZE THERAPEUTI...
|
Healthcare | 1.81% | 1.62% |
#20
6
Prev: #26
|
2.7 |
—
|
351,400 | 9.4% |
P
S
|
4,083,969 | $111,002,277 | 2025 Q1 | 13F Filing | 2026-09-30 | 2026-11-16 | |||
|
COAG
HEMAB THERAPEUT...
|
Healthcare | 1.80% | 1.93% |
#21
Prev: #21
|
1.2 |
—
|
-14,297 | -0.4% |
P
S
|
3,587,796 | $110,647,629 | 2026 Q2 | 13F Filing | 2026-09-30 | 2026-11-16 | |||
|
GMAB
CALL
GENMAB A/S
|
CALL Option | 1.60% | 1.20% |
#22
9
Prev: #31
|
1.1 |
—
|
-240,000 | -8.0% |
P
S
|
2,760,000 | $98,463,000 | 2024 Q4 | 13F Filing | 2026-09-30 | 2026-11-16 | |||
|
MLTX
MOONLAKE IMMUNO...
|
Healthcare | 1.54% | 1.98% |
#23
3
Prev: #20
|
2.6 |
—
|
1,106,265 | 15.8% |
P
S
|
8,105,290 | $94,831,893 | 2023 Q2 | 13F Filing | 2026-09-30 | 2026-11-16 | |||
|
ORKA
ORUKA THERAPEUT...
|
Healthcare | 1.45% | 2.67% |
#24
11
Prev: #13
|
0.6 |
—
|
-856,226 | -44.5% |
P
S
|
1,069,774 | $89,101,476 | 2024 Q3 | 13F Filing | 2026-09-30 | 2026-11-16 | |||
|
WGS
GENEDX HOLDINGS...
|
Healthcare | 1.41% | 0.70% |
#25
17
Prev: #42
|
3.6 |
—
|
500,000 | 71.4% |
P
S
|
1,200,000 | $86,760,000 | 2026 Q2 | 13F Filing | 2026-09-30 | 2026-11-16 | |||
|
TEM
CALL
TEMPUS AI INC
|
CALL Option | 1.33% | — |
#26
Prev: #—
|
4.0 |
—
|
1,000,000 | — |
NEW
|
1,000,000 | $81,900,000 | 2026 Q3 | 13F Filing | 2026-09-30 | 2026-11-16 | |||
|
COGT
COGENT BIOSCIEN...
|
Healthcare | 1.30% | 1.13% |
#27
5
Prev: #32
|
3.0 |
—
|
500,000 | 25.0% |
P
S
|
2,500,000 | $80,050,000 | 2024 Q1 | 13F Filing | 2026-09-30 | 2026-11-16 | |||
|
GHRS
GH RESEARCH PLC
|
Healthcare | 1.27% | 1.30% |
#28
2
Prev: #30
|
1.5 |
—
|
no change | no change |
P
S
|
3,333,334 | $78,266,682 | 2021 Q4 | 13F Filing | 2026-09-30 | 2026-11-16 | |||
|
BCAX
BICARA THERAPEU...
|
Healthcare | 1.24% | 1.77% |
#29
4
Prev: #25
|
1.5 |
—
|
no change | no change |
P
S
|
4,100,000 | $76,301,000 | 2024 Q3 | 13F Filing | 2026-09-30 | 2026-11-16 | |||
|
LTGO
LATIGO BIOTHERA...
|
Healthcare | 1.20% | — |
#30
Prev: #—
|
4.0 |
—
|
4,408,322 | — |
NEW
|
4,408,322 | $73,618,978 | 2026 Q3 | 13F Filing | 2026-09-30 | 2026-11-16 | |||
|
CLDX
CELLDEX THERAPE...
|
Healthcare | 1.12% | 1.59% |
#31
4
Prev: #27
|
0.4 |
—
|
-813,619 | -27.7% |
P
S
|
2,125,532 | $68,888,492 | 2024 Q4 | 13F Filing | 2026-09-30 | 2026-11-16 | |||
|
BBIO
BRIDGEBIO PHARM...
|
Healthcare | 0.95% | — |
#32
Prev: #—
|
3.9 |
—
|
885,882 | — |
NEW
|
885,882 | $58,291,036 | 2021 Q4 | 13F Filing | 2026-09-30 | 2026-11-16 | |||
|
AVTX
AVALO THERAPEUT...
|
Healthcare | 0.90% | 0.97% |
#33
2
Prev: #35
|
1.4 |
—
|
no change | no change |
P
S
|
3,610,000 | $55,341,300 | 2024 Q3 | 13F Filing | 2026-09-30 | 2026-11-16 | |||
|
ALMS
ALUMIS INC
|
Healthcare | 0.90% | 2.60% |
#34
20
Prev: #14
|
2.4 |
—
|
1,121,188 | 17.7% |
P
S
|
7,469,746 | $55,201,423 | 2026 Q1 | 13F Filing | 2026-09-30 | 2026-11-16 | |||
|
ALT
ALTIMMUNE INC
|
Healthcare | 0.90% | 0.85% |
#35
3
Prev: #38
|
1.4 |
—
|
no change | no change |
P
S
|
19,250,000 | $55,055,000 | 2026 Q2 | 13F Filing | 2026-09-30 | 2026-11-16 | |||
|
N/A
ATTOVIA THERAPE...
|
|
Unknown | 0.90% | — |
#36
Prev: #—
|
3.9 |
—
|
3,207,138 | — |
NEW
|
3,207,138 | $54,970,345 | — | 13F Filing | 2026-09-30 | 2026-11-16 | ||
|
BLLN
BILLIONTOONE IN...
|
Healthcare | 0.87% | — |
#37
Prev: #—
|
3.8 |
—
|
500,000 | — |
NEW
|
500,000 | $53,220,000 | 2025 Q4 | 13F Filing | 2026-09-30 | 2026-11-16 | |||
|
ACRS
ACLARIS THERAPE...
|
Healthcare | 0.80% | 0.72% |
#38
2
Prev: #40
|
1.3 |
—
|
no change | no change |
P
S
|
9,345,000 | $49,154,700 | 2023 Q1 | 13F Filing | 2026-09-30 | 2026-11-16 | |||
|
CRMD
CORMEDIX INC
|
Healthcare | 0.79% | 0.72% |
#39
2
Prev: #41
|
1.3 |
—
|
no change | no change |
P
S
|
6,274,076 | $48,310,385 | 2025 Q3 | 13F Filing | 2026-09-30 | 2026-11-16 | |||
|
EWTX
EDGEWISE THERAP...
|
Healthcare | 0.76% | — |
#40
Prev: #—
|
3.8 |
—
|
1,148,817 | — |
NEW
|
1,148,817 | $46,641,970 | 2022 Q3 | 13F Filing | 2026-09-30 | 2026-11-16 | |||
|
VSTM
VERASTEM INC
|
Healthcare | 0.75% | 0.32% |
#41
13
Prev: #54
|
1.3 |
—
|
no change | no change |
P
S
|
5,740,850 | $46,213,843 | 2025 Q4 | 13F Filing | 2026-09-30 | 2026-11-16 | |||
|
DFTX
DEFINIUM THERAP...
|
Healthcare | 0.62% | 1.88% |
#42
19
Prev: #23
|
0.2 |
—
|
-1,750,000 | -63.6% |
P
S
|
1,000,000 | $38,060,000 | 2026 Q1 | 13F Filing | 2026-09-30 | 2026-11-16 | |||
|
GENB
GENERATE BIOMED...
|
Healthcare | 0.61% | 0.33% |
#43
10
Prev: #53
|
3.2 |
—
|
1,173,634 | 88.0% |
P
S
|
2,507,449 | $37,661,884 | 2026 Q2 | 13F Filing | 2026-09-30 | 2026-11-16 | |||
|
MBX
MBX BIOSCIENCES...
|
Healthcare | 0.61% | 1.39% |
#44
15
Prev: #29
|
0.2 |
—
|
-1,092,569 | -63.1% |
P
S
|
640,000 | $37,516,800 | 2024 Q3 | 13F Filing | 2026-09-30 | 2026-11-16 | |||
|
ANIP
ANI PHARMACEUTI...
|
Healthcare | 0.59% | — |
#45
Prev: #—
|
3.7 |
—
|
500,000 | — |
NEW
|
500,000 | $36,325,000 | 2023 Q2 | 13F Filing | 2026-09-30 | 2026-11-16 | |||
|
VRDN
VIRIDIAN THERAP...
|
Healthcare | 0.57% | 0.96% |
#46
10
Prev: #36
|
0.2 |
—
|
-1,881,710 | -52.4% |
P
S
|
1,711,030 | $35,230,108 | 2021 Q4 | 13F Filing | 2026-09-30 | 2026-11-16 | |||
|
HROW
HARROW INC
|
Healthcare | 0.54% | 0.60% |
#47
4
Prev: #43
|
2.2 |
—
|
100,000 | 10.3% |
P
S
|
1,069,000 | $32,925,200 | 2026 Q2 | 13F Filing | 2026-09-30 | 2026-11-16 | |||
|
OBX
OBSIDIAN THERAP...
|
Healthcare | 0.47% | — |
#48
Prev: #—
|
3.7 |
—
|
2,120,050 | — |
NEW
|
2,120,050 | $29,108,287 | 2026 Q3 | 13F Filing | 2026-09-30 | 2026-11-16 | |||
|
CRVS
CORVUS PHARMACE...
|
Healthcare | 0.47% | 0.54% |
#49
5
Prev: #44
|
1.2 |
—
|
no change | no change |
P
S
|
2,491,939 | $28,707,137 | 2026 Q1 | 13F Filing | 2026-09-30 | 2026-11-16 | |||
|
NBIX
NEUROCRINE BIOS...
|
Healthcare | 0.46% | — |
#50
Prev: #—
|
3.7 |
—
|
200,000 | — |
NEW
|
200,000 | $28,368,000 | 2023 Q3 | 13F Filing | 2026-09-30 | 2026-11-16 |
Showing 1-50 of 87 holdings